A Center for Science in the Public Interest study suggests the FDA missed "obvious errors" in reviewing some gene-altered crops. According to CSPI, the FDA's procedures are filled with holes and as a result, continued safety of genetically engineered plants cannot be ensured. The FDA says it has always been open to changing its review process if new biotech products demand greater scrutiny.

Related Summaries